Where Neuroscience Meets AI to Redefine Drug Discovery
Meet the Team
Dr Simon Stringer
Professor Gonçalo Bernardes
Professor Ana Domingos
Co-Founder and Chief AI Officer
(University of Oxford)
Professor Ana Domingos
Professor Gonçalo Bernardes
Professor Ana Domingos
Co-Founder and Advisor
(In Vivo)
(University of Oxford)
Professor Gonçalo Bernardes
Professor Gonçalo Bernardes
Professor Gonçalo Bernardes
Co-Founder and Advisor (Drug Development (Cambridge University)
Nigel Brooksby
Nigel Brooksby
Professor Gonçalo Bernardes
Co-Founder and Chairman
Rakesh Roshan
Nigel Brooksby
Rakesh Roshan
Co-Founder and Co-Chair
Dr Kam Pooni
Nigel Brooksby
Rakesh Roshan
Co-Founder and CEO
Adam Williams
Adam Williams
Adam Williams
Co-Founder and CCO
Paul Jesson
Adam Williams
Adam Williams
CFO
Symbiotic.blue is building something purposefully different
innovative approach to drug discovery by integrating Generative AI and neuroscience-inspired methodologies to develop multi-pathway therapeutics for complex diseases:
Generative AI
AI that can create new content — like text, images, molecules, or even biological models — rather than just analysing existing data. It learns patterns from massive datasets and then generates new outputs that follow similar rules..
Hierarchical Feature Binding (HFB)
Inspired by how the human brain processes complex information, enabling the AI to model biology in a more contextual, layered way.
Unimolecular Polypharmacy (UniMP)
Designed to generate molecules that can simultaneously act on multiple biological targets, increasing potential efficacy and reducing development risk.